CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (LITERATURE REVIEW)
Abstract
Significance of C. difficile and A/B toxins produced by this bacteria was shown in the literature review on antibiotic-associated diarrhea. Problems concerning epidemiology, clinical symptomatology, complications from this disease, diagnostics as well as appropriate approaches to therapy were discussed. Antibiotic-associated diarrhea is a serious disease requiring careful and thoughtful approaches to antibiotic treatment. Risk of hospital-acquired antibiotic-associated diarrhea related to massive use of antimicrobial drugs in Russia and other countries makes this problem very important.
About the Authors
N. V. Dmitrieva
Laboratory of Microbiological diagnosis and treatment of infections, N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
24, Kashirskoye Shosse, 115478-Moscow
Russian Federation
24, Kashirskoye Shosse, 115478-Moscow
I. А. Klyuchnikova
Laboratory of Microbiological diagnosis and treatment of infections, N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
24, Kashirskoye Shosse, 115478-Moscow
Russian Federation
24, Kashirskoye Shosse, 115478-Moscow
I. I. Shilnikova
Laboratory of Microbiological diagnosis and treatment of infections, N.N. Blokhin Russian Cancer Research Center RAMS, Moscow
Russian Federation
24, Kashirskoye Shosse, 115478-Moscow
Russian Federation
24, Kashirskoye Shosse, 115478-Moscow
References
1. Жуков Н.В. Диарея у пациентов, получающих цитостатическую терапию // Сопроводительная терапия в онкологии. 2005. № 3. С. 2–10.
2. Лобзин Ю.В., Захаренко С.М., Иванов Г.А. Современные представления об инфекции Clostridium difficile // Клин. микроб. и антимикроб. тер. 2002. № 3 (4). С. 200–232.
3. Шевола Д., Дмитриева Н.В. Осложнения антибактериальной терапии: дисбактериоз кишечника и псевдомембранозный колит // Послеоперационные инфекционные осложнения / Под ред. Н.В. Дмитриевой, И.Н. Петуховой. М.: Практическая медицина, 2013. С. 363–378.
4. Шульпекова Ю.О. Антибиотикоассоциированная диарея // Русский медицинский журнал. 2007. № 6 (15). С. 1–6.
5. Bakken J.S. Fecal bacteriotherapy for recurrent Clostridium difficile infection // J. Anaerobe. 2009. Vol. 15. P. 285–289.
6. Balassiano I.T., Santos-Filho J., Barros de Oliveira M.P. et al. An outbreak case of Clostridium difficile-associated diarrhea among elderly inpatients of an intensive care unit of a tertiary hospital in Rio de Janeiro, Brasil // J. Diagn. Microbiol. Infect. Dis. 2010. Vol. 68. P. 449–455.
7. Bauer M.P., Kuijper E.J., Van Dissel J.T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI) // J. Clin. Microbiol. Infect. 2009. Vol. 15 (12). P. 1067–1079.
8. Bauer M.P., Van Dissel J.T. Alternative strategies for Clostridium difficile infection // J. Antimicrob. Agents. 2009. Vol. 33 (1). P. 51–56.
9. Bishara J., Bloch Y., Garty M. et al. Antimicrodial resistance of Clostridium difficile isolates in a tertiary medical center, Israel // J. Diagn. Microdiol. Infect. Dis. 2006. Vol. 54. P. 141–144.
10. Burns D.A., Heap J.T., Minton N.P. The diverse sporulation characteristics of Clostridium difficile clinical isolates are not associated with type // J. Anaerobe. 2010. Vol. 16. P. 618–622. 11. Carman R.J., Genheimer C.W., Rafii F. et al. Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea // J. Anaerobe. 2009. Vol. 15. P. 244–248.
11. Chung Chih-Huan, Wu Chi-Jung, Lee Hsin-Chun et al. Clostridium difficile infection at a medical center in Southern Taiwan: incidence, clinical features and prognosis // J. Microbiol. Immunol. Infect. 2010. Vol. 43 (2). P. 119–125.
12. Cohen S.H., Peroling D.N., Johnson S. et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) // Infect. Control. Hosp. Epidemiol. 2010. Vol. 31 (5). P. 431–455.
13. Dawson L.F., Valiente E., Wren B.W. Clostridium difficile – a continually evolving and problematic pathogen // Infect. Genet. Evolut. 2009. Vol. 9. P. 1410–1417.
14. Deneve C., Janoir C., Poilane I. et al. New trends in Clostridium difficile virulence and pathogenesis // J. Antimicrob. Agents. 2009. Vol. 33 (1). P. 24–28.
15. Elliott B., Reed R., Chang B.J., Riley T.V. Bacteremia with a large clostridial toxin-negative, binary toxin-positive strain of Clostridium difficile // J. Anaerobe. 2009. Vol. 15. P. 249–251.
16. Garey K.W., Dao-Tran T.K., Jiang Z.D. et al. A clinical risk index for Clostridium difficile infection in hospitalized patients receiving broadspectrum antibiotics // J. Hosp. Infect. 2008. Vol. 70. P. 142–147.
17. Germansky K.A., Kelly C.P. Clostridium difficile infection // Hosp. Med. Clin. 2012. Vol. 1. Issue 1. P. e69–e86.
18. Goldenberg S.D., Dieringer T., French G.L. Detection of toxigenic Clostridium difficile in diarrheal stool by rapid real-time polymerase chain reaction // J. Diagn. Microbiol. Infect. Dis. 2010. Vol. 67. P. 304–307.
19. Goldstein E.J.C., Citron D.M., Tyrrell K.L., Warren Y.A. Bactericidal activity of televancin, vancomycin and metronidazole against Clostridium difficile // J. Anaerobe. 2010. Vol. 16. P. 220–222.
20. Kee V.R. Clostridium difficile infection in older adults: a review and update on its management // American J. Geriatric. Pharmacotherapy. 2012. Vol. 10 (1). P. 14–24.
21. McFarland L.V. Evidence-based review of probiotics for antibioticassociated diarrhea and Clostridium difficile infections // J. Anaerobe. 2009. Vol. 15. P. 274–280.
22. Meader E., Mayer M.M., Gasson M.J. et al. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system // J. Anaerobe. 2010. Vol. 16. P. 549–554.
23. Musgrave C.R., Bookstaver P.B., Sutton S.S., Miller A.D. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection // Int. J. Infect. Dis. 2011. Vol. 15. P. 438–448.
24. Raveh D., Rabinowitz B., Breuer G.S. et al. Risk factors for Clostridium difficile toxin-positive nosocomial diarrhea // J. Antimicrob. Agents. 2006. Vol. 28. P. 231–237.
25. Trejo F.M., Minnaard J., Perez P.F., De Antoni G.L. Inhibition of Clostridium difficile growth and adhesion to by Bifidobacterium supernatants // J. Anaerobe. 2006. Vol. 12. P. 186–193.
26. Verdoorn B.P., Orenstein R., Rosenblatt J.E. et al. High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease a severity // J. Diagn. Mircobiol. Infect. Dis. 2010. Vol. 66. P. 24–28.
27. Zheng L., Citron D.M., Genheimer C.W. et al. Molecular characterization and antimicrobial susceptibilities of extraintestinal Clostridium difficile isolates // J. Clin. Microbiol. 2007. Vol. 13. P. 114–120.
Review
For citations:
Dmitrieva N.V., Klyuchnikova I.А., Shilnikova I.I. CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA (LITERATURE REVIEW). Siberian journal of oncology. 2014;(1):46-53. (In Russ.)
Views:
619
Email this article 
